SNGX News and Press, Soligenix Inc. From 04/24/23

2023-04-24 09:25:20 ET Soligeni ( NASDAQ: SNGX ) is trading 12% higher premarket after it said it had submitted a meeting request to the U.S. Food and Drug Administration to begin discussions regarding the design of a second, Phase 3 trial testing HyBryte to treat a rare cance...

Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma PR Newswire Meeting expected to occur approximately 30 days from the FDA's receipt...

2023-04-14 08:05:10 ET Soligenix ( NASDAQ: SNGX ) shares fell ~12% premarket on Friday after the biopharmaceutical company disclosed that the U.S. FDA is seeking more positive results to accept an NDA filing for its HyBryte drug. HyBryte is a light-activated ointment for...

Soligenix Provides Regulatory Update on HyBryte™ PR Newswire PRINCETON, N.J. , April 14, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produc...

Soligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302 PR Newswire PRINCETON, N.J. , April 5, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-...

Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma PR Newswire Update on FDA Meeting Outcome Expected by End of April PRINCETON, N.J. , April 3, 2023 ...

2023-03-31 08:16:08 ET Soligenix press release ( NASDAQ: SNGX ): FY GAAP EPS of -$4.81 misses by $3.68 . Revenue of $0.9M (+12.5% Y/Y) beats by $0.7M . As of Dec. 31, 2022, the company's cash position was ~$13.4M. For further details see: Soligenix GA...

Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results PR Newswire PRINCETON, N.J. , March 31, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and...

2023-03-09 08:22:11 ET Soligenix ( NASDAQ: SNGX ) said it has submitted a request for a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss a letter in which the agency declined to accept for review an application seeking approval of HyBryte. In Febr...

Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma PR Newswire Meeting expected to occur approximately 30 days from the FDA's receipt of meeting request PRINCETON, N....